iShares Morningstar Multi Asset Income ETF
0.00 (0.0%)


Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Day High


52 Week Range


Day Low
Company Name Etf Ticker Symbol Market Type
iShares Morningstar Multi Asset Income ETF IYLD AMEX Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
0.00 0.0% 19.0665 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 17.83 - 22.46
Last Trade Time Type Quantity Etf Price Currency
- 0  19.0665 USD

iShares Morningstar Multi Asset Income ETF Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 143.00M 7.50M 7.50M  -  - - 5.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 5.67% 03/02/23 - -

more financials information »

News iShares Morningstar Mult...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IYLD Message Board. Create One! See More Posts on IYLD Message Board See More Message Board Posts

IYLD Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week19.00519.1018.7318.9016,2320.06150.32%
1 Month19.2119.54518.6919.0315,898-0.1435-0.75%
3 Months19.1220.3618.6919.7742,299-0.0535-0.28%
6 Months18.3820.3617.8319.2260,0490.68653.74%
1 Year22.280122.4617.8319.7055,469-3.21-14.42%
3 Years20.1625.0217.8321.4447,842-1.09-5.42%
5 Years24.8826.0817.5922.8256,076-5.81-23.37%

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.